

MicroRNAs in
Glioblastoma: Insights
and Implications
Unveiling the Role of
MicroRNAs in Brain
Tumor Biology and
Therapy


**IULIU HATIEGANU UNIVERSITY OF
MEDICINE AND PHARMACY**

**CLUJ- NAPOCA
ROMANIA**

Iceland 
Liechtenstein
Norway grants


MicroRNAs and Cancer

- MicroRNAs can act as oncogenes or tumor suppressors, influencing cancer initiation, progression, and metastasis.
- Dysregulation of miRNAs is a common feature in cancer, leading to abnormal cell growth and differentiation.
- Understanding the role of miRNAs in cancer can offer insights into disease mechanisms and identify new targets for therapy.



Introduction to Glioblastoma

- Glioblastoma is the most common and aggressive form of brain cancer in adults.
- Despite advances in treatment, the prognosis remains poor, with a median survival of about 15 months post-diagnosis.
- Treatment typically involves a combination of surgery, radiation therapy, and chemotherapy, aiming to prolong survival and improve quality of life.




MicroRNAs (miRNAs) are small, non-coding RNA molecules, about 22 nucleotides in length, that play a crucial role in regulating gene expression.

They bind to complementary sequences on target messenger RNAs (mRNAs), usually resulting in gene silencing.


Their regulation of gene expression is essential for normal development and functioning, as well as in the pathology of various diseases, including cancer.

Overview of MicroRNAs



MicroRNAs in Glioblastoma

- In glioblastoma, certain miRNAs are upregulated, contributing to tumor growth and survival, such as miR-21, which inhibits apoptosis and promotes proliferation.
- Conversely, some miRNAs are downregulated, like miR-34a, which normally functions as a tumor suppressor by targeting multiple oncogenes.
- These alterations in miRNA expression contribute to the aggressive nature of glioblastoma.



1. Main role of MicroRNAs in glioblastoma. Studies conducted in the last dec

Recent Research

- Recent studies have identified miR-124 and miR-128 as critical regulators of glioblastoma stem cell differentiation, offering new targets for therapy.
- Another study showed that inhibition of miR-10b suppresses tumor growth and extends survival in glioblastoma animal models.
- These findings highlight the potential of miRNA-targeted therapies to complement existing treatments.

| S. No. | miRNA Name | Expression in Glioblastoma | Role in GBM |
|--------|-------------|----------------------------|------------------|
| 1. | miR-21 | up-regulated [34] | oncomiR |
| 2. | miR-93 | up-regulated [35] | oncomiR |
| 3. | miR-10b | up-regulated [35] | oncomiR |
| 4. | miR-196a | up-regulated [36] | oncomiR |
| 5. | miR-221/222 | up-regulated [37] | oncomiR |
| 6. | miR-182 | up-regulated [38] | oncomiR |
| 7. | miR-7 | down-regulated [39] | tumor suppressor |
| 8. | miR-128 | down-regulated [40] | tumor suppressor |
| 9. | miR-124/137 | down-regulated [41] | tumor suppressor |
| 10. | miR-101 | down-regulated [42] | tumor suppressor |
| 11. | miR-181 | down-regulated [40,43] | tumor suppressor |
| 12. | miR-146a | down-regulated [44] | tumor suppressor |
| 13. | miR-137 | down-regulated [45] | tumor suppressor |
| 14. | miR-34a | down-regulated [43] | tumor suppressor |

The correlation of microRNA-181a and target genes with poor prognosis of glioblastoma patients





Figure 1. The expression of miR-181a in normal and GBM tissues. (A) Hierarchical clustering for differential miRNAs in 3 paired GBM tissues derived from GEO database (GSE65626-GPL19117). (B) Expression levels of miR-181a in long-lived individuals, normal tissues and various cancers derived from the GEO database (GSE61741). Expression levels of miR-181a in GBM vs. normal tissues derived from the (C) GEO dataset GSE61741 and (D) GSE25632-GPL8179.



miRNAs Expression Deregulation

| | | |
|-------------|-----------|---|
| miR-206 | miR-4477a | ↓ |
| miR-4795-5p | miR-4311 | |
| miR-4796-3p | | |

miR-451b ↑

$p < 0.0001$
Significantly deregulation in brain tumor compared to control

Diagnostic Biomarkers

| microRNA | AUC | p-value |
|-------------|------|---------|
| miR-206 | 1.00 | <0.0001 |
| miR-4477a | 0.93 | <0.0001 |
| miR-451b | 0.89 | <0.0001 |
| miR-4311 | 0.95 | <0.0001 |
| miR-4795-5p | 0.91 | <0.0001 |
| miR-4796-3p | 0.91 | <0.0001 |

These microRNAs act as good diagnostic markers for glioma patients

Survival Analysis


| microRNA | p-value |
|-------------|---------|
| miR-206 | <0.01 |
| miR-4477a | <0.04 |
| miR-451b | <0.02 |
| miR-4795-5p | 0.004 |
| miR-4796-3p | 0.02 |

MicroRNAs deregulation associated with poor survival of glioma patients


Prognostic Biomarkers


| microRNA | wald | p-value |
|-------------|------|---------|
| miR-206 | 4.6 | 0.03 |
| miR-4477a | 4.27 | 0.02 |
| miR-451b | 5.12 | 0.02 |
| miR-4311 | 3.69 | 0.05 |
| miR-4795-5p | 9.41 | 0.0002 |
| miR-4796-3p | 7.12 | 0.02 |


These microRNAs act as worse/poor prognostic factors for glioma patients






3D *in vitro* modeling of glioblastoma multiforme (GBM) (reproduced with permission from ¹¹¹). The GBM tissues are derived from the tumor mass isolated from the patients. Then different kinds of cells are dissociated from the tumor mass. These are: neurons, astrocytes, oligodendrocytes, tumor cells, tumor associated macrophages. *In-vitro* modeling is done in several ways: spheroid formation, organoid formation, formation of 3D scaffolds with the use of engineered biomaterials (reprinted with permission from ²¹⁶), 3D bioprinting etc. The bioprinting procedure and bioprinted mini brains are depicted using a schematic. A) Bioprinting procedure depicting the fabrication of cell-laden GelMA-gelatin bioinks and the subsequent two-step bioprinting of mini-brains. B) Close-up and cross-sectional view of the bioprinted mini-brains containing living cells (adapted with permission from ¹³⁰).







b miRNA expression profile from patients' data



Disclaimer: This document was realised with the EEA Financial Mechanism 2014-2021 financial support. Its content (text, photos, videos) does not reflect the official opinion of the Programme Operator, the National Contact Point and the Financial Mechanism Office. Responsibility for the information and views expressed therein lies entirely with the author(s).